Garland Surgical (Cohort 8.0) close €3.5 million seed round and prepare for Series A funding

---

Accelerate Cohort 8.0 founders Garland Surgical have closed a successful €3.5 million seed round and are now preparing for Series A funding.

---

We have some fantastic news to share from BetaDen Accelerate Cohort 8.0 alumni Garland Surgical who have successfully closed a €3.5 million seed round and are now in preparation for Series A funding for their TriActiv hip replacement technology.

Garland Surgical, led by CEO & founder Simon Mifsud have secured €2.1 million in equity funding alongside €1.4 million in grant funding from Malta Enterprise for their novel hip replacement solution - the TriActiv Hip, that seeks to revolutionise the hip-replacement market with a longer-lasting more stable solution.

Garland will use their seed round to fund continued product development and early clinical activity, whilst they prepare for a larger Series A funding round that will ultimately aim to push the TriActiv Hip towards commercialisation and clinical trials.

We'd like to offer a massive congratulations to Garland on all their incredibly well-deserved success and we look forward to seeing the continued growth of their game-changing innovation.

To read the full press release from Garland Surgical announcing their seed round close, use the link here.